Matches in Nanopublications for { ?s ?p "[These standards were used in two JAK2 p.V617F assays, which were used to support clinical studies of ruxolitinib (Jakafi(®)) in myelofibrosis, a real-time polymerase chain reaction assay for initial screening of all samples, and a novel single-nucleotide polymorphism typing (SNaPshot)-based assay for samples with less than 5% mutant allele burden.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- NP1064470.RAGWIT_fl1uCrSNEevyDu7HzZyH4VAZRp3KVWO6fbWQHg130_assertion description "[These standards were used in two JAK2 p.V617F assays, which were used to support clinical studies of ruxolitinib (Jakafi(®)) in myelofibrosis, a real-time polymerase chain reaction assay for initial screening of all samples, and a novel single-nucleotide polymorphism typing (SNaPshot)-based assay for samples with less than 5% mutant allele burden.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1064470.RAGWIT_fl1uCrSNEevyDu7HzZyH4VAZRp3KVWO6fbWQHg130_provenance.
- NP1064471.RAk5HaXIJdvuvHHQAS24QtR09vweZFgFMimqQDjCO_NB4130_assertion description "[These standards were used in two JAK2 p.V617F assays, which were used to support clinical studies of ruxolitinib (Jakafi(®)) in myelofibrosis, a real-time polymerase chain reaction assay for initial screening of all samples, and a novel single-nucleotide polymorphism typing (SNaPshot)-based assay for samples with less than 5% mutant allele burden.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1064471.RAk5HaXIJdvuvHHQAS24QtR09vweZFgFMimqQDjCO_NB4130_provenance.